INS and Insulin resistance: Additionally, reduced HNF1B expression in the liver causes insulin resistance via impaired insulin signaling, accelerates gluconeogenesis, and increases dipeptidyl peptidase-4 level.[32,33] The above findings indicate that liraglutide, which improves hepatic insulin resistance,[34] shows potential as a treatment option for MODY 5.